• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于评估复发多发性骨髓瘤患者死亡风险的新型风险分层算法:回顾性病历审查中的外部验证

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.

作者信息

Hájek Roman, Gonzalez-McQuire Sebastian, Szabo Zsolt, Delforge Michel, DeCosta Lucy, Raab Marc S, Bouwmeester Walter, Campioni Marco, Briggs Andrew

机构信息

Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic

Amgen Europe GmbH, Rotkreuz, Switzerland.

出版信息

BMJ Open. 2020 Jul 14;10(7):e034209. doi: 10.1136/bmjopen-2019-034209.

DOI:10.1136/bmjopen-2019-034209
PMID:32665382
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7365483/
Abstract

OBJECTIVES AND DESIGN

A novel risk stratification algorithm estimating risk of death in patients with relapsed multiple myeloma starting second-line treatment was recently developed using multivariable Cox regression of data from a Czech registry. It uses 16 parameters routinely collected in medical practice to stratify patients into four distinct risk groups in terms of survival expectation. To provide insight into generalisability of the risk stratification algorithm, the study aimed to validate the risk stratification algorithm using real-world data from specifically designed retrospective chart audits from three European countries.

PARTICIPANTS AND SETTING

Physicians collected data from 998 patients (France, 386; Germany, 344; UK, 268) and applied the risk stratification algorithm.

METHODS

The performance of the Cox regression model for predicting risk of death was assessed by Nagelkerke's R, goodness of fit and the C-index. The risk stratification algorithm's ability to discriminate overall survival across four risk groups was evaluated using Kaplan-Meier curves and HRs.

RESULTS

Consistent with the Czech registry, the stratification performance of the risk stratification algorithm demonstrated clear differentiation in risk of death between the four groups. As risk groups increased, risk of death doubled. The C-index was 0.715 (95% CI 0.690 to 0.734).

CONCLUSIONS

Validation of the novel risk stratification algorithm in an independent 'real-world' dataset demonstrated that it stratifies patients in four subgroups according to survival expectation.

摘要

目的与设计

最近利用来自捷克登记处的数据进行多变量Cox回归分析,开发出一种新的风险分层算法,用于估算复发多发性骨髓瘤患者开始二线治疗后的死亡风险。该算法使用医疗实践中常规收集的16个参数,根据生存预期将患者分为四个不同的风险组。为深入了解该风险分层算法的可推广性,本研究旨在使用来自三个欧洲国家专门设计的回顾性病历审核的真实世界数据,对该风险分层算法进行验证。

参与者与研究背景

医生收集了998例患者的数据(法国386例;德国344例;英国268例)并应用了风险分层算法。

方法

通过Nagelkerke's R、拟合优度和C指数评估Cox回归模型预测死亡风险的性能。使用Kaplan-Meier曲线和风险比评估风险分层算法区分四个风险组总体生存情况的能力。

结果

与捷克登记处的数据一致,风险分层算法的分层性能显示出四组之间在死亡风险上有明显差异。随着风险组的增加,死亡风险翻倍。C指数为0.715(95%置信区间0.690至0.734)。

结论

在一个独立的“真实世界”数据集中对新的风险分层算法进行验证表明,该算法可根据生存预期将患者分为四个亚组。

相似文献

1
Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.用于评估复发多发性骨髓瘤患者死亡风险的新型风险分层算法:回顾性病历审查中的外部验证
BMJ Open. 2020 Jul 14;10(7):e034209. doi: 10.1136/bmjopen-2019-034209.
2
Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting.复发环境下多发性骨髓瘤患者新型风险分层算法的方法学
Oncol Ther. 2019 Dec;7(2):141-157. doi: 10.1007/s40487-019-00100-5. Epub 2019 Nov 3.
3
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.新型复发性多发性骨髓瘤风险分层算法的建立与验证。
Br J Haematol. 2019 Nov;187(4):447-458. doi: 10.1111/bjh.16105. Epub 2019 Aug 6.
4
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.多发性骨髓瘤风险分层指数在常规临床实践中的验证:捷克骨髓瘤小组单克隆丙种球蛋白血症登记处数据分析。
Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21.
5
Does the SORG Algorithm Predict 5-year Survival in Patients with Chondrosarcoma? An External Validation.SORG 算法能否预测软骨肉瘤患者的 5 年生存率?一项外部验证。
Clin Orthop Relat Res. 2019 Oct;477(10):2296-2303. doi: 10.1097/CORR.0000000000000748.
6
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.了解多发性骨髓瘤的死亡率:一项欧洲回顾性图表审查的结果。
Eur J Haematol. 2019 Aug;103(2):107-115. doi: 10.1111/ejh.13264. Epub 2019 Jun 18.
7
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.根据新的基于虚弱的预后预测模型(Myeloma Risk Profile-MRP)评估英国真实世界老年初诊骨髓瘤患者的虚弱特征和临床结局。
PLoS One. 2022 Jan 11;17(1):e0262388. doi: 10.1371/journal.pone.0262388. eCollection 2022.
8
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.英国、法国和意大利复发多发性骨髓瘤患者的医疗资源利用情况。
J Med Econ. 2018 May;21(5):450-467. doi: 10.1080/13696998.2017.1421546. Epub 2018 Jan 10.
9
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.肌萎缩侧索硬化症患者的预后:个体化预测模型的建立和验证。
Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26.
10
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.意大利和英国 GIMEMA 多中心、横断面研究:IMWG 虚弱评分与复发/难治性多发性骨髓瘤患者健康相关生活质量特征的相关性。
Lancet Healthy Longev. 2022 Sep;3(9):e628-e635. doi: 10.1016/S2666-7568(22)00172-6.

引用本文的文献

1
Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites.白人多发性骨髓瘤死亡预测模型的建立与验证
Evid Based Complement Alternat Med. 2022 Aug 16;2022:3050199. doi: 10.1155/2022/3050199. eCollection 2022.
2
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.基于卡非佐米的治疗的深度应答者的疗效和安全性特征:来自 ASPIRE 和 ENDEAVOR 的亚组分析。
Leukemia. 2021 Jun;35(6):1732-1744. doi: 10.1038/s41375-020-01049-5. Epub 2020 Oct 16.

本文引用的文献

1
Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting.复发环境下多发性骨髓瘤患者新型风险分层算法的方法学
Oncol Ther. 2019 Dec;7(2):141-157. doi: 10.1007/s40487-019-00100-5. Epub 2019 Nov 3.
2
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.新型复发性多发性骨髓瘤风险分层算法的建立与验证。
Br J Haematol. 2019 Nov;187(4):447-458. doi: 10.1111/bjh.16105. Epub 2019 Aug 6.
3
Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.
开发多发性骨髓瘤初始概念模型以支持临床和卫生经济学决策制定。
MDM Policy Pract. 2019 Jan 17;4(1):2381468318814253. doi: 10.1177/2381468318814253. eCollection 2019 Jan-Jun.
4
Established and Novel Prognostic Biomarkers in Multiple Myeloma.多发性骨髓瘤中已确立的和新的预后生物标志物
Am Soc Clin Oncol Educ Book. 2017;37:548-560. doi: 10.1200/EDBK_175175.
5
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.复发多发性骨髓瘤治疗的最新进展:对治疗决策的影响
Br J Haematol. 2017 Oct;179(2):198-218. doi: 10.1111/bjh.14780. Epub 2017 May 30.
6
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.修订后的国际分期系统在未经选择的新诊断和复发多发性骨髓瘤患者中的临床应用。
Blood Cancer J. 2017 Feb 17;7(2):e528. doi: 10.1038/bcj.2017.13.
7
Revised International Staging System Applied to Real World Multiple Myeloma Patients.应用于真实世界多发性骨髓瘤患者的修订国际分期系统
Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.
8
Multiple myeloma: patient outcomes in real-world practice.多发性骨髓瘤:真实世界实践中的患者结局
Br J Haematol. 2016 Oct;175(2):252-264. doi: 10.1111/bjh.14213. Epub 2016 Jul 13.
9
Multiple myeloma: practice patterns across Europe.多发性骨髓瘤:欧洲各地的诊疗模式
Br J Haematol. 2016 Oct;175(1):66-76. doi: 10.1111/bjh.14193. Epub 2016 Jun 13.
10
Clinical characteristics of patients with relapsed multiple myeloma.复发性多发性骨髓瘤患者的临床特征。
Cancer Treat Rev. 2015 Dec;41(10):827-35. doi: 10.1016/j.ctrv.2015.07.005. Epub 2015 Jul 31.